CRP and familial hyperaldosteronism: The combination of bempedoic acid along with atorvastatin and ezetimibe has been associated with a fundamental and long-term reduction of cholesterol by nearly 50% and C-reactive protein by 40% across FH patients at high risk of ASCVD with no major toxicities [91].